Source - LSE Non-Regulatory
RNS Number : 4237O
Synairgen plc
03 October 2023

Synairgen plc

('Synairgen' or the 'Company')

Synairgen appoints Dr Marcin Mankowski as Chief Medical Officer

·      New full-time role created as Synairgen progresses clinical development strategy

Southampton, UK - 3 October 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta, today announces the appointment of Dr Marcin Mankowski as Chief Medical Officer (CMO), effective immediately.

Marcin is a seasoned pharmaceutical physician and drug developer with more than 27 years of pharmaceutical industry experience and a strong background in infectious diseases and respiratory medicine. Marcin joins Synairgen on a full-time basis having worked with the Company as acting CMO and a clinical trials consultant since 2018.   

Prior to joining Synairgen, Marcin was Co-Founder and Chief Executive Officer at tranScrip Ltd, a leading contract drug development business, where he played an integral strategic role in both driving investment as well as leading a vast range of projects across all stages of drug development and multiple therapy areas.

Commenting on Marcin's full time appointment today, Richard Marsden, CEO of Synairgen, said: "I am delighted that Marcin will be joining us as CMO in a full time capacity.  Since 2018, he has been supporting and guiding us on our clinical trials and his appointment today underlines his belief in our drug. Marcin's in-depth knowledge of the Company and SNG001 as well as his strong track record in leading the strategy, design and implementation of global clinical development programmes, will be invaluable to us as we prepare to enter further clinical trials of SNG001."

Dr Marcin Mankowski, newly appointed CMO of Synairgen, added: "I look forward to be working more closely with and supporting the team at Synairgen as it progresses towards more targeted clinical trials of SNG001 to maximise the benefits of treatment and address the high unmet medical need."


For further enquiries, please contact: 


Synairgen plc 

Tel: + 44 (0) 23 8051 2800 


ICR Consilium (Financial Media and Investor Relations) 

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

Tel: +44 (0) 20 3709 5700 



Notes for Editors 


Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.


Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Synairgen PLC (SNG)

+0.01p (+0.25%)
delayed 17:30PM